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Abstract
Background: Brain metastases (BrM) develop in 20–40% of cancer patients and represent an unmet clinical need. Limited ac-
cess of drugs into the brain because of the blood-brain barrier is at least partially responsible for therapeutic failure, necessi-
tating improved drug delivery systems.
Methods: Green fluorescent protein (GFP)-transduced murine and nontransduced human hematopoietic stem cells (HSCs)
were administered into mice (n¼10 and 3). The HSC progeny in mouse BrM and in patient-derived BrM tissue (n¼6) was
characterized by flow cytometry and immunofluorescence. Promoters driving gene expression, specifically within the BrM-
infiltrating HSC progeny, were identified through differential gene-expression analysis and subsequent validation of a series
of promoter-green fluorescent protein-reporter constructs in mice (n¼5). One of the promoters was used to deliver tumor ne-
crosis factor–related apoptosis-inducing ligand (TRAIL) to BrM in mice (n¼17/21 for TRAIL vs control group).
Results: HSC progeny (consisting mostly of macrophages) efficiently homed to macrometastases (mean [SD] ¼ 37.6% [7.2%] of
all infiltrating cells for murine HSC progeny; 27.9% mean [SD] ¼ 27.9% [4.9%] of infiltrating CD45þ hematopoietic cells for
human HSC progeny) and micrometastases in mice (19.3–53.3% of all macrophages for murine HSCs). Macrophages were also
abundant in patient-derived BrM tissue (mean [SD] ¼ 8.8% [7.8%]). Collectively, this provided a rationale to optimize the deliv-
ery of gene therapy to BrM within myeloid cells. MMP14 promoter emerged as the strongest promoter construct capable of
limiting gene expression to BrM-infiltrating myeloid cells in mice. TRAIL delivered under MMP14 promoter statistically signifi-
cantly prolonged survival in mice (mean [SD] ¼ 19.0 [3.4] vs mean [SD] ¼ 15.0 [2.0] days for TRAIL vs control group; two-sided
P¼ .006), demonstrating therapeutic and translational potential of our approach.
Conclusions: Our study establishes HSC gene therapy using a myeloid cell–specific promoter as a new strategy to target BrM.
This approach, with strong translational value, has potential to overcome the blood-brain barrier, target micrometastases,
and control multifocal lesions.
Metastatic brain tumors are the most frequent intracranial
tumors. They develop in 20–40% of all cancer patients, and
mostly originate from lung cancer, breast cancer, and mela-
noma (1,2). The median survival time of patients with brain
metastases (BrM) is only 4–19 months (1,3). Systemic chemo-
therapies have had little success in the treatment of BrM (1,2),
which is thought to be at least partially because of the blood-
brain barrier (BBB) limiting delivery of drugs into the brain (4,5).
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Despite partial disruption of the BBB in BrM, the vessel perme-
ability in experimental BrM reaches only approximately 15% of
that seen in other organs (4). Thus, novel approaches for the ef-
fective delivery of drugs to BrM are urgently required.
A handful of studies have explored neuronal and mesenchy-
mal stem cells to deliver gene therapy to BrM in preclinical
models (6–9), whereas hematopoietic stem cells (HSCs) have not
yet been investigated in this context. We previously observed a
substantial homing of macrophages, which are derived from
HSCs, to BrM (10). Advantages of HSCs in comparison to other
stem cell therapies include the ability to isolate them in large
quantities and well-established procedures for their therapeutic
use. Recent clinical trials of HSC gene therapy for Wiskott-
Aldrich syndrome (11), X-linked severe combined immunodefi-
ciency (12), b-thalassaemia (13), and adrenoleukodystrophy [a
severe demyelinating brain disease (14,15)] showed remarkable
results. The disadvantage of HSCs in the context of therapies,
however, is the wide distribution of their progeny in different
tissues, leading to systemic rather than localized delivery of
transferred genes and thus potential systemic toxicities. To ad-
dress this challenge, our goal was to develop a strategy for lenti-
viral gene transfer into HSCs that would restrict the delivery of
transgenes to BrM.
Methods
In Vivo BrM Models
Six- to eight-week-old female C57Bl/6J and NSG mice were pur-
chased from Charles River Laboratories, UK. Humanized NSG
mice engrafted with human CD34þ cells used in immune cell
quantification studies were purchased from JAX. Using stereo-
taxic apparatus (intracranial implantation model), we injected
1105 cancer cells into the striatum (16) or into the left internal
carotid artery (10,17). Metacam (15 mg) was administered subcu-
taneously, and an inhalable anaesthetic (Isoflurane) was used
during surgery. Bioluminescence imaging was performed using
IVIS Spectrum (Perkin Elmer). All surgery and animal care pro-
cedures followed recommendations by the University of Leeds
Animal Welfare & Ethical Review Committee and were per-
formed under the approved UK Home Office project license in
line with the Animal (Scientific Procedures) Act 1986.
Bone Marrow Reconstitution
Bone marrow was flushed from the long bones of C57Bl/6J or
C57Bl/6-Tg(Ubiquitin C [UBC]-green fluorescent protein
[GFP])30Scha/J mice (Jackson Laboratories). HSCs were isolated
using the Anti-Sca-1 Micro Bead Kit (Miltenyi) and were injected
intravenously into lethally irradiated (8.45 Gy) C57Bl/6J mice ei-
ther immediately (2.5105 cells) or following transduction with
a respective lentiviral vector overnight (multiplicity of infection
[MOI] 20–50; 1106 cells). Human CD34þ bone marrow–derived
HSCs (DV Biologics) were transduced with pFUGW (18) (MOI 50)
overnight and injected intravenously (2105 cells) into suble-
thally irradiated (225 cGy) NSG mice.
In Vivo Survival Study
HSCs were lentivirally transduced with MMP14: GFP or MMP14:
tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)
construct (MOI 20) and injected intravenously into lethally irra-
diated (8.45 Gy) C57Bl/6J mice (6-week-old females). Following
bone marrow reconstitution (7 weeks later), 1105 PyMT cells
were injected intracranially. Mice were examined daily for tu-
mor growth–related symptoms, and symptoms were recorded
according to the scoring sheet in our Home Office project li-
cense. At the onset of morbidity, the mice were culled, and brain
tissue isolated for quantitative polymerase chain reaction
(qPCR) analysis. Three mice were excluded from statistical anal-
yses of the survival study: one mouse from each group because
of non-tumor growth–related symptoms necessitating the ani-
mals be euthanized at an early time point and one mouse from
the MMP14: GFP group because of failure to initiate tumor
growth.
Microarray Gene–Expression Analysis
Biological replicates used for analysis were as follows: n¼ 4 for
PyMT BrM and the spleens of PyMT BrM-bearing mice; n¼ 1 for
the bone marrow of PyMT BrM-bearing mice; n¼ 2 for EO771
BrM, naı¨ve spleens, and naı¨ve bone marrow. Toward the experi-
mental endpoint, reduced size of spleens with black areas sug-
gesting cell death was observed in mice with intracranial EO771
tumors. Consequently, we were unable to isolate viable spleen
and bone marrow cells from this model despite repeating the
experiment three times. Because of these difficulties, spleens
and bone marrow isolated from naı¨ve mice were used instead.
Human Tissue
Human breast cancer BrM tissue and matched blood were
obtained from the Leeds General Infirmary, the Leeds Teaching
Hospitals Trust. Written informed consent was obtained from
each individual under the ethical approval (Ref: 15/YH/0080) of
the Leeds Multidisciplinary Research Tissue Bank or under re-
search project ethical approval 18/EM/0159, approved by the
Nottingham 1 Research Ethics Committee, UK.
Statistical Analyses
Data were analyzed using a two-tailed t test or one-way analysis
of variance with multiple comparisons, as stated in the figure
legends (statistical significance cutoff ¼ 0.05). Error bars repre-
sent SDs. Statistical significance in the survival study was deter-
mined via a two-sided log-rank test using GraphPad Prism 8.
Further methods are provided in the Supplementary
Methods (available online).
Results
Interaction of Myeloid Cells with BrM
To allow for in vivo detection, PyMT (10,19) and EO771 (20) murine
breast cancer cell lines were tagged with Discosoma sp. red fluo-
rescent protein and Firefly luciferase (EO771-DF and PyMT-DF).
Both models formed large single lesions following intracranial
implantation in C57Bl/6J mice (16) (Figure 1A Supplementary
Figure 1A, available online). They also efficiently colonized the
brain after administration into the internal carotid artery (10,17),
resulting in multiple cancer lesions including micro- (few cells)
and macrometastases (Figure 1B; Supplementary Figure 1B, avail-
able online), which grew in a close association with vasculature
(Supplementary Figure 1C, available online). Thus, our models
home to and colonize the brain, mimic multifocal metastatic
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lesions, and allow for the study of micro- and macrometastases,
thereby recapitulating key aspects of the clinical disease.
As previously reported (10), CD11bþ myeloid cells were
abundantly infiltrating large intracranial tumors and microme-
tastases in EO771-DF and PyMT-DF models (Figure 1C).
Moreover, we detected substantial infiltration of F4/80þ micro-
glia/macrophages within macrometastases in the brain in a
spontaneous melanoma model (21) (Supplementary Figure 1F,
available online). To determine the proportion of BrM-infiltrat-
ing cells originating from the HSCs as opposed to the yolk sack–
derived brain-resident microglia (22), we generated bone mar-
row chimeras through transplantation of GFPþ HSCs into irradi-
ated mice, resulting in mean (SD) ¼ 73.4% (6.6%) GFPþ cells in
the blood (Figure 1D; Supplementary Figure 1D, available
Figure 1. Myeloid cells in preclinical models of brain metastases. A) Discosoma sp. red fluorescent protein/Fluc (DF)–tagged EO771 and PyMT breast cancer cells give rise to a
single large cancer lesion in the brain following intracranial implantation (H&E staining); n¼4. B) Administration of EO771-DF cancer cells into the internal carotid artery
gives rise to micro- and macrometastases 2 weeks post-injection (n¼3/6 for EO771-DF/PyMT-DF). Scale bar ¼ 50mm. C) Macrometastases (intracranial implantation model)
and micrometastases (carotid artery model) in the brain are infiltrated by CD11bþ myeloid cells (group sizes as in A and B). Scale bars ¼ 50mm (left panels) and 20mm (right
panels). D–F) Bone marrow in C57Bl/6J mice was ablated by irradiation, followed by transplantation of hematopoietic stem cells (HSCs) isolated from the transgenic mice
expressing green fluorescent protein (GFP) downstream of the Ubiquitin C (UBC) promoter. Seven weeks later, tumors were generated by intracranial implantation of cancer
cells. Infiltration of GFPþ bone marrow–derived myeloid cells (CD11bþ) was quantified by flow cytometry at 2 weeks post–cancer cell injection (E). Percentage of GFPþ cells
within the CD11bþ cell population is shown in (F); n¼5.G) Quantification of GFPþ HSC progeny per mm3 tissue within PyMT brain tumors and normal tumor-adjacent brain
tissue (n¼3, P¼ .03. Statistically significant difference was determined with the two-tailed Student’s t test. H) Representative dot plots of flow cytometry for quantifying the
percentage of CD45high cells within CD11bþF4/80þ population and percentage of GFPþ cells within CD11bþF4/80þCD45high cell population infiltrating PyMT tumors (n¼3).
I) Gating strategy and quantification of GFPþ and CD49dþP2RY12- cells within CD45þCD11bþLy6C-Ly6G- microglia/macrophages infiltrating PyMT tumors (n¼3).
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online). The vast majority of CD11bþ cells within BrM were
GFPþ (mean [SD] ¼ 95.7% [1.5%] in EO771, mean [SD] ¼ 90.9%
[4.1%] in the PyMT model) and thus derived from the HSCs
(Figure 1F). Strikingly, GFPþCD11bþ cells accounted for mean
(SD) ¼ 49.2% (1%) (EO771) and mean (SD) ¼ 29.3% (7%) (PyMT) of
all cells within BrM (Figure 1E). Infiltration of GFPþ HSC progeny
into normal tumor-adjacent brain was statistically significantly
lower than infiltration into tumors (mean [SD] ¼ 4.5  104 [1.5 
104] vs mean [SD] ¼ 119.0 [114.0] cells per mm3 tissue within
tumors vs tumor-adjacent brain; two-sided P¼ .03) (Figure 1G).
CD11bþF4/80þ macrophages/microglia represented mean
(SD) ¼ 32.7% (11.1%) (EO771) and mean (SD) = 12.5% (4.0%) (PyMT)
of all intratumoral cells (Supplementary Figure 2A, available on-
line). Whereas macrophages are generally CD45high and microglia
CD45low (23), under specific conditions, microglia can also upre-
gulate CD45 expression (24). Notably, mean (SD) ¼ 98.5% (1.0%) of
CD11bþF4/80þ cells (EO771 and PyMT tumors) were CD45high
(Figure 1H), and mean (SD) ¼ 98.3% (0.7%) of F4/
80þCD11bþCD45high cells were GFPþ (Figure 1H; Supplementary
Figure 2B, available online) and, therefore, derived from HSCs and
not microglia. Additionally, we used recently reported macro-
phage [CD49d/ITGA4 (25)] and microglia-specific [P2RY12 (25–28)]
cell surface markers. Within CD45þCD11bþLy6G-Ly6C- macro-
phages/microglia, mean (SD) ¼ 85.4% (6.7%) (EO771) and mean
(SD) ¼ 98.1% (1.3%) of cells (PyMT) were GFPþ (Figure 1I;
Supplementary Figure 2C, available online), and mean (SD) ¼
82.2% (2.2%) (EO771) and mean (SD) = 96.1% (2.3%) of these cells
(PyMT) were CD49dþP2RY12- (Figure 1I; Supplementary Figure
2D, available online), further confirming that the majority of mye-
loid cells are HSC-derived macrophages.
Within the F4/80þCD11bþ population infiltrating normal
brain, mean (SD) ¼ 66.6% (4.4%) of the cells were CD45low, and
only mean (SD) ¼ 8.9% (6.0%) within this population were HSC-
derived GFPþ cells (Supplementary Figure 2E, available online).
Interestingly, CD45lowGFPþ cells retained low P2RY12 expres-
sion comparable to CD45highGFPþ macrophages
(Supplementary Figure 2F, available online), suggesting they are
distinct from brain-resident microglia with high P2RY12 expres-
sion, which is in line with other studies (28).
Notably, a proportion of myeloid cells in tumors could origi-
nate directly from a subpopulation of transplanted HSCs with-
out hematopoiesis as shown previously for normal brain (28,29).
Regardless, based on their capability to deliver transgenes to
BrM, and based on their high proportion in intracranial tumors,
we reasoned that HSC-derived myeloid cells could be used as
cellular vehicles for the delivery of therapeutic genes to BrM.
Homing of Genetically Modified HSC Progeny to BrM
To validate HSCs and their progeny as cellular vehicles, we used GFP
as a model gene to be delivered to BrM. Murine HSCs were transduced
with a lentiviral vector pFUGW, expressing GFP under the Ubiquitin C
(UBC) promoter (18,30) and transplanted into lethally irradiated C57Bl/
6J mice. BrM were generated by intracranial EO771-DF implantation
(Figure 2A). The progeny of GFP-transduced HSCs efficiently homed
to BrM (Figure 2B). As expected, GFPþ HSC progeny were also present
in other organs to variable extent (Figure 2C).
In line with experiments using HSCs from GFP: UBC trans-
genic mice, the F4/80þ population contained almost exclusively
macrophages (Supplementary Figure 1E, available online). CD45þ
cells represented mean (SD) ¼ 37.6% (7.2%) of all cells within
tumors. The majority of CD45þ cells were CD11bþ myeloid cells
(mean [SD] ¼ 26.5% [6.0%] of all cells), consisting mostly of F4/80þ
macrophages (mean [SD] ¼ 22.4% [5.5%] of all cells) (Figure 2, D
and E), whereas only mean (SD) ¼ 2.8% (0.6%) of all cells belonged
to other myeloid cell populations. The highest percentage of
GFPþ cells (mean [SD] ¼ 43.2% [38.6%]) was detected within mac-
rophages. Notably, the infiltration of hematopoietic cells, includ-
ing macrophages, into BrM remained unaltered following whole-
body irradiation and HSC transplantation, as compared with the
nonirradiated mice (Supplementary Figure 3A, available online).
The progeny of GFP-transduced HSCs also efficiently tracked
down micrometastases and closely associated with small EO771
lesions (Figure 2, F and G). The majority of micrometastases-
associated cells were CD11bþ and F4/80þ (Figure 2H), with 19.3–
53.3% expressing GFP (Figure 2I). The ratio of cancer cells to
CD11bþ cells (1:1 to 1:2) was similar to the intracranial model
(Figure 2H). All micrometastases were associated with CD11bþ
cells, and more than 90% contained CD11bþGFPþ cells
(Supplementary Figure 3B, available online). Thus, we demon-
strated that the genetically engineered HSC progeny, mostly
consisting of macrophages, efficiently homed to large BrM and
to micrometastases and can deliver genetically expressed mole-
cules to the close proximity of cancer cells.
Validation of Human HSCs and Their Progeny as
Cellular Vehicles
With clinical translation in mind, we next validated human
HSCs (hHSCs). Engraftment of CD34þ hHSCs in sublethally irra-
diated NOD/SCID/IL2rcKO (NSG) mice, previously shown to re-
sult in mature and functional human hematopoietic cells (31),
was followed by intracranial implantation of the human brain-
homing breast cancer cell line MDA-MB-231/brain (32)
(Figure 3A). Further, mean (SD) ¼ 39.7% (9.9%) of hematopoietic
cells in the blood and mean (SD) ¼ 27.9% (4.9%) within tumors
were of human origin (Figure 3B), with T and B cells being pre-
dominant in the blood, and T cells in brain tumors
(Supplementary Figure 4A, available online).
Focusing on myeloid cells within tumors, this population
(mean [SD] = 13.4% [7.4%] of human cells) consisted of granulo-
cytes (mean [SD] =6.1% [4.2%]) and macrophages mean (SD) ¼
(5.3% [3.1%]). In line with murine HSC models, mean (SD) ¼
98.6% (2.4%) of human CD45þCD11bþCD16-CD66B-CD14þ cells
were CD49dþ macrophages (25) (Figure 3D). When transduced
with pFUGW before transplantation into mice, hHSC progeny
could also deliver GFP to brain tumors (Figure 3E;
Supplementary Figure 4, B and C, available online).
Substantial infiltration of CD45þ hematopoietic cells and
CD68þ macrophages/microglia was further detected in patient
BrM originating from breast and lung cancer by immunofluo-
rescence (Figure 3, F and G; Supplementary Figure 4, D, avail-
able online). Analysis of human BrM by flow cytometry
revealed that the predominant population within
CD45þCD11bþCD16-CD66B-CD14þ microglia/macrophages
were CD49dþ macrophages (mean [SD] ¼ 92.8% [12.1%]; n¼ 6)
(Figure 3H; Supplementary Figure 4E, available online). Total
percentage of macrophages within patient BrM varied between
2.7 and 23.3% (average of mean [SD] ¼ 8.8% [7.8%]; n¼ 6)
(Figure 3I). In summary, these data demonstrated strong paral-
lels between human tissue and our preclinical models.
Identification of Gene Promoters for BrM-Specific
Delivery of Therapeutic Molecules within Myeloid Cells
To enable predominant delivery of gene therapy to BrM, we
sought to identify gene promoters that are upregulated in BrM-
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infiltrating myeloid cells. GFPþCD11bþ cells were isolated from
brain tumors, bone marrow, and the spleen of mice with chime-
ric GFPþ bone marrow (Figure 4A), bearing EO771 and PyMT
tumors, respectively, or from naı¨ve mice and subjected to a
genome-wide gene-expression analysis. Data from both cancer
models were initially combined, and BrM were compared with
the pooled spleen/bone marrow group. Differential gene-ex-
pression analysis identified 5972 statistically significantly
differentially expressed probes (False Discovery Rate [FDR] <
1%; Figure 4B), including chemokines, matrix metalloprotei-
nases, and genes associated with macrophage activation/polari-
zation (10,34,35). Expression of macrophage polarization
markers (36–39) differed strongly between the intratumoral and
the spleen/bone marrow–derived myeloid cells (Figure 4, C and
D). Notably, 119 probes showed greater than 10-fold and 9
probes greater than 100-fold upregulation in BrM. However,
Figure 2. Genetically modified hematopoietic stem cell (HSC) progeny in the context of macro- and micrometastases in the brain. A) Murine HSCs transduced with len-
tiviral pFUGW vector were transplanted into lethally irradiated recipient mice, and tumors were generated by intracranial implantation of EO771-DF cells. B) Detection
of pFUGW-transduced HSC progeny (green fluorescent protein [GFP]þ) in intracranial tumors generated according to the scheme in (A) by immunofluorescence (n¼7).
Scale bar ¼ 200 mm. C) Quantification of pFUGW-transduced HSC progeny (GFPþ) in different tissues by flow cytometry; n¼3. D) Quantification of immune cell popula-
tions within EO771 intracranial tumors by flow cytometry. Total percentage of individual cell populations, as well as the proportion of cells derived from pFUGW-trans-
duced HSCs is shown; n¼7. E) Immunofluorescence staining of intracranial EO771 tumors for macrophages/microglia (F4/80þ) and GFP (n¼4). Scale bars ¼ 50 mm. F)
Murine HSCs transduced with lentiviral pFUGW vector were transplanted into lethally irradiated recipient mice, followed by administration of EO771-DF cells into the
internal carotid artery. G) CD11bþGFPþ progeny of HSCs was observed in close association with EO771-DF micrometastases in the brain. Fluorescence images were
obtained by confocal microscopy (n¼ 3). Scale bars ¼ 50 mm. H) Cancer cells and micrometastases-associated cells belonging to different hematopoietic cell subpopula-
tions were counted on immunofluorescence images; 4–8 micrometastases-containing coronal brain sections per animal (n¼3) were quantified. I) Percentages of GFPþ
cells within micrometastases-associated hematopoietic cell populations were quantified using immunofluorescence images and overall percentages of GFPþ cells in
matched blood by flow cytometry (group sizes as in H).
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only some of these probes were strongly upregulated in both
cancer models. Expression of the latter (Supplementary Figure
5A, available online) was further validated by polymerase chain
reaction (PCR) in CD11bþGFPþ and total cells isolated from dif-
ferent tissues (Figure 4E; Supplementary Figure 5B, available on-
line). Among genes that showed the most specific expression in
BrM-infiltrating CD11bþ cells were Spp1, Mmp14, Trem2, Dab2,
and Emp1. Analysis in the EO771 model (mice transplanted with
GFP-transduced HSCs) at the protein level revealed expression of
DAB2, MMP14, and SPP1 in GFPþ BrM-infiltrating cells, but not in
the spleen or bone marrow (Figure 5A; Supplementary Figure 6A,
available online). DAB2, MMP14, and SPP1 were also consistently
expressed in CD68þ microglia/macrophages in patient-derived
breast cancer BrM (n¼ 4), while their expression was absent
from the patient-matched blood (Figure 5B; Supplementary
Figure 7, available online). In summary, this suggested a strong
potential of DAB2, MMP14, and SPP1 promoters to improve the
specificity in the context of HSC gene therapy.
Figure 3. Human hematopoietic stem cells (HSCs) and their progeny as cellular vehicles targeting brain metastases. A) Tumors were generated in humanized NSG mice
(JAX) 3–4 months after engraftment of human HSCs (hHSCs) by intracranial implantation of MDA-MB-231/brain cells. B) The percentage of human hematopoietic cells
(hCD45þ) in blood and brain tumors was quantified by flow cytometry (n¼3). C) Myeloid cell subpopulations within MDA-MB-231/brain tumors were quantified by flow
cytometry (n¼ 3). D) Percentage of CD49dþ macrophages within human CD45þCD11bþCD16-CD66B-CD14þ population in intracranial MDA-MB-231/brain tumors was
quantified by flow cytometry (n¼3). Representative dot plots are shown. E) Lentiviral pFUGW vector–transduced hHSCs were transplanted into sublethally irradiated
NSG mice, and tumors were generated by intracranial implantation of MDA-MB-231/brain cells 3–4 months later (n¼4). Detection of green fluorescent protein-positive
human hematopoietic cells in intracranial tumors was performed by immunofluorescence. Scale bar ¼ 50mm. F, G) Hematopoietic cells and macrophages in patient
brain metastases specimens originating from breast cancer (F) and lung cancer (G) were detected by immunofluorescence (n¼3 per cancer type). To visualize cancer
cells, adjacent sections were stained for pan-cytokeratin (breast cancer brain metastases [BrM]) or vimentin (lung cancer BrM) and costained for human CD45 (hemato-
poietic cells) human CD68 (macrophages). Scale bars ¼ 100mm. H) Percentage of CD49dþ macrophages within CD45þCD11bþCD16-CD66B-CD14þ microglia/macrophage
population (25) in patient BrM originating from different primary cancer types as indicated in (I) was quantified by flow cytometry (n¼ 6). Representative dot plots are
shown. I) Percentage of CD45þCD11bþCD16-CD66B-CD14þCD49dþmacrophages within total cell population in patient BrM (n¼6). RCC¼ renal cell carcinoma.
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Validation of BrM-Specific Myeloid Promoter Constructs
in Preclinical Models
Respective fragments of MMP14, SPP1 (two lengths), and DAB2
promoters were cloned into lentiviral vectors upstream of GFP
(Figure 6A). HSCs transduced with these vectors were trans-
planted into lethally irradiated mice, followed by generation of
intracranial EO771 tumors (Figure 6B). As expected, UBC pro-
moter–driven GFP expression could be detected in CD45þ cells in
all tissues without a tissue-specific pattern. By contrast, MMP14
and SPP1 promoters displayed statistically significantly higher
GFP mean fluorescence intensity (MFI; a measure of promoter
strength; see Supplementary Table 2, available online for P val-
ues) in CD45þ cells infiltrating BrM as compared with other tis-
sues (Figure 6, C and D). Promoter strength (GFP MFI) was higher
for the MMP14 promoter construct. To account for differences in
the viral copy number (VCN) between different promoter con-
structs and tissues, we normalized MFI to VCN (MFI/VCN). As
expected, VCN was higher in the bone marrow and spleen as
compared with the brain tumors, whereas MFI/VCN was highest
in the brain tumors. This confirmed an increased activity of
MMP14 and SPP1 promoters in BrM-infiltrating vs spleen/bone
marrow-infiltrating HSC progeny. In line with the MFI analysis,
the MFI:VCN ratio was also the highest for the MMP14 promoter
Figure 4. Identification of genes specific for brain metastases-infiltrating myeloid cells. A) Tumors in the brain were generated by intracranial implantation of cancer cells
(untagged) into chimeric mice with green fluorescent protein (GFP)-tagged bone marrow (derived from Ubiquitin C [UBC]: GFP mice). CD11bþGFPþ cells were isolated from the
brain tumors, spleens, and the bone marrow and subjected to RNA microarray analysis. Spleens and bone marrow isolated from naı¨ve mice were used instead of those iso-
lated from EO771 brain metastases (BrM)-bearing mice. B) A heat map of the top 150 probes differentially expressed between bone marrow-derived myeloid cells
(CD11bþGFPþ) isolated from BrM (Br) and myeloid cells isolated from the spleen (S) bone marrow (BM); n¼4 for PyMT BrM and the spleens; n¼1 for the PyMT bone marrow;
n¼2 for EO771 BrM, naı¨ve spleens, and naı¨ve bone marrow. C) Differential expression of macrophage polarization–associated genes between BrM- and the spleen/bone mar-
row–derived myeloid cells. D) Functional protein interaction network of 33 murine macrophage polarization-associated genes, as identified using Search Tool for the Retrieval
of Interacting Genes (STRING) (33). Individual nodes represent genes connected by color-coded lines of interaction according to software predictions (confidence score set to
0.4). E) Expression of top 10 genes upregulated in myeloid cells within brain metastases was validated by semiquantitative polymerase chain reaction. GADPH was used as a
control. Representative DNA gels are shown. The quantification of the data is shown in Supplementary Figure S4B (available online). HSC¼ hematopoietic stem cell.
A
R
T
IC
LE
T. Andreou et al. | 7
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz181/5566500 by U
niversity of Leeds user on 08 January 2020
(Supplementary Figure 8A, available online). With the exception
of the lungs, the percentage of GFPþ cells was higher in BrM than
in other tissues for MMP14 and SPP1 promoter-reporter con-
structs (Figure 6D; Supplementary Table 1, available online).
Based on these data, we focused on the MMP14 promoter.
Using mice that have received GFPþ HSCs from UBC: GFP trans-
genic mice, the expression of MMP14 in GFPþ cells in the brain was
further analyzed by using immunofluorescence. GFPþ cells within
normal brain were mainly located at the choroid plexus and ventri-
cle walls, with lower numbers found within the brain parenchyma,
cortex, cerebellum, and at the brain surface (Supplementary
Figure 9, available online). In contrast to strong MMP14 expression
in tumor-infiltrating GFPþ cells, GFPþ cells within normal brain
were MMP14-negative (Supplementary Figure 9, available online).
In line with this, analysis of previously published gene-expression
data (25,27,28) revealed a statistically significantly higher
expression of Mmp14 in HSC-derived tumor-infiltrating macro-
phages vs HSC-derived normal brain-engrafting microglia-like cells
(Supplementary Figure 8B, available online). In summary, this
demonstrated an increased specificity of MMP14 expression in
tumor-infiltrating hematopoietic cells.
Notably, CD45þ cells infiltrating BrM in a spontaneous mela-
noma model (21) also expressed MMP14 (Supplementary
Figure 6B, available online), confirming that the MMP14 pro-
moter is also active in BrM-infiltrating hematopoietic cells in a
more physiological model and in the absence of irradiation.
TRAIL Gene Therapy Delivered under the MMP14
Promoter
Delivery of proapoptotic molecule TRAIL (9) was chosen as a
proof of principle of the therapeutic applicability of our
approach. After confirming the expression of the TRAIL con-
struct under the UBC promoter (Figure 7A) and the sensitivity of
PyMT cancer cells to the TRAIL in vitro (Figure 7, B and C), the
TRAIL was placed under the MMP14 promoter fragment in a len-
tiviral vector and was used for in vivo efficacy study in the intra-
cranial PyMT model (Figure 7D). Survival analysis revealed a
statistically significantly prolonged survival of mice following
TRAIL delivery in HSCs (mean [SD] ¼ 19 [3.4] vs 15 [2.0] days for
MMP14: TRAIL vs MMP14: GFP; two-sided P¼ .006) (Figure 7E), to-
gether with increased Tnsf10 (TRAIL gene) expression in brain
tumors as determined by qPCR (Figure 7F). In summary, our
data establish a new platform for the delivery of therapeutic
genes to BrM.
Discussion
In this study, we developed a strategy for the delivery of thera-
peutic genes to BrM within the HSC progeny, using gene pro-
moters specific for tumor-infiltrating myeloid cells. The latter
were identified as the optimal cellular vehicles because of their
high presence in BrM, their uniform distribution within tumors,
and predominant homing to the tumor rather than healthy
brain. Moreover, this strategy is expected to circumvent the
BBB, control micrometastases, and enable a simultaneous tar-
geting of multifocal BrM that pose a challenge for surgical re-
moval. Use of myeloid cell–specific promoters is expected to
limit the delivery of gene therapy mainly to tumors and thereby
minimize systemic side effects. Whereas a similar approach us-
ing the Tie2-promoter has been previously used to deliver ther-
apy to glioma in Tie2-expressing monocytes (40), here, we chose
to focus on the most abundant hematopoietic cell population in
Figure 5. Validation of expression of genes specific for brain metastases (BrM)-infiltrating myeloid cells in preclinical models and clinical specimens. A) The activity of gene
promoters in the progeny of pFUGW-transduced hematopoietic stem cells was assessed in BrM, the spleen, and bone marrow of EO771 tumor-bearing mice (intracranial im-
plantation model) with chimeric green fluorescent protein (GFP)þ bone marrow by performing immunofluorescence staining for the respective proteins and GFP (n¼3).
Colocalization of DAB2, MMP14, and SPP1, respectively, with GFP is shown in merge images. Nuclei are stained with DAPI. Scale bars ¼ 50mm. B) Human BrM tissue and do-
nor-matched blood were costained for the macrophage marker CD68 and for DAB2, MMP14, and SPP1, respectively (n¼4). Three further brain metastases specimens with
donor-matched blood samples are shown in Supplementary Figure S6 (available online). Nuclei are stained with DAPI. Scale bars¼ 20mm.
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BrM. In summary, our study establishes a novel approach for
targeting of BrM with HSC gene therapy.
Lentiviral gene transfer demonstrated an excellent safety
record (41,42), with promising results in patients (11–15). We
demonstrated a strong potential for the clinical translation of
HSC gene therapy for BrM by demonstrating the BrM-homing
capacity of hHSCs, the abundant infiltration of myeloid cells,
and the activity of identified myeloid promoters in human BrM.
Because MMP14 is upregulated in brain-infiltrating macro-
phages in Alzheimer disease, multiple sclerosis, and stroke (43),
this promoter could be also used for gene therapy in noncancer-
ous brain disorders accompanied by strong myeloid cell infiltra-
tion (14,44–49). Moreover, our approach has the potential for
simultaneous targeting of multiorgan metastases.
Several preclinical models were used in this study to address
the key clinically relevant features of BrM, including the context
of an intact immune system (syngeneic models), validation of
human HSCs (humanized NSG mice), and analysis of macrome-
tastases (intracranial model) and micrometastases (carotid ar-
tery model). Because approximately 15–60% of BrM remain
undiagnosed (50,51), micrometastases in the brain may be quite
common. Established BrM have also been shown to invade sur-
rounding tissue (52,53). Thus, targeting of dormant
micrometastases and those remaining after surgical removal
(54,55) represents an unmet clinical need that could be
addressed with our strategy.
In the present proof-of-principle study we used the MMP14
promoter. However, our study has several limitations. First, the
initial differential gene-expression analysis was limited to the
comparison of myeloid cells between brain tumors, bone mar-
row, and the spleen. Although we subsequently analyzed addi-
tional tissues, several tissues containing mature macrophages
(ie, gut, liver, and fat) were not investigated because of technical
limitations, and thus a possibility remains that our promoters
are active in these tissues. Second, we reasoned that assessing
the promoter strength at the protein level (flow cytometry) is
superior, as proteins/peptides rather than mRNA represent ef-
fector molecules in therapeutic applications. However, use of an
additional method (ie, qPCR quantification of transgene expres-
sion) would strengthen our findings. Third, we used whole-body
irradiation before HSC transplantation. With clinical translation
in mind, it will be important to determine in the future which
HSC transplantation approach (ie, busulfan or treosulfan [29])
results in the highest engraftment of HSC progeny within
tumors while minimizing engraftment within the healthy brain
and other organs.
Figure 6. Validation of promoter constructs in preclinical models. A) Scheme of promoter-reporter constructs used for in vivo validation. The beginning and end of pro-
moter fragments in relation to the transcriptional start site are indicated. B) Murine hematopoietic stem cells transduced with respective lentiviral promoter-reporter
constructs (MOI 20) were transplanted into recipient mice, and tumors were generated by intracranial implantation of untagged EO771 cells. C) Representative flow cy-
tometry dot plots showing green fluorescent protein (GFP) expression downstream of individual promoter constructs in EO771 brain metastases-infiltrating hemato-
poietic cells (n¼ 5). D) Percentage of GFPþ hematopoietic cells displayed against the GFP mean fluorescence intensity. Dots represent individual brain tumors, the
lungs, and spleen/bone marrow/blood samples. The vertical line marks the background of GFP expression based on tissues isolated from the naı¨ve mice (right).
Individual values and statistical analysis are provided in Supplementary Tables 1 and 2 (available online) (n¼5).
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